<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485614</url>
  </required_header>
  <id_info>
    <org_study_id>0431-083</org_study_id>
    <nct_id>NCT01485614</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety &amp; Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)</brief_title>
  <official_title>A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety of the addition of sitagliptin, and its
      effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2
      diabetes mellitus (T2DM) with inadequate glycemic control. The primary hypothesis for this
      study is that sitagliptin reduces A1C more than placebo after 20 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is of approximately 56 weeks in duration, including a screening period of up to 1
      week, a 1-week single-blind placebo run-in period, a 20-week placebo-controlled, double blind
      treatment period [Phase A] and a 34-week double-blind active controlled treatment period
      [Phase B] during which participants randomized to the placebo arm who have not initiated
      glycemic rescue therapy with metformin during Phase A will receive metformin (in a blinded
      manner). A telephone contact will be performed 14 days after the last dose of study
      medication to assess for any serious adverse events (SAEs).

      Two arms of the study were removed from the study by a protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2012</start_date>
  <completion_date type="Anticipated">January 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in A1C</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AE)</measure>
    <time_frame>Up to 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued study medication due to an AE</measure>
    <time_frame>Up to 54 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in A1C at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an A1C target of &lt;7.0%, &lt;6.5% at Week 20</measure>
    <time_frame>Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an A1C target of &lt;7.0%, &lt;6.5% at Week 54</measure>
    <time_frame>Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG) at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proinsulin at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proinsulin at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proinsulin/insulin ratio at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proinsulin/insulin ratio at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Homeostatic Model Assessment of β-cell function (HOMA-β) at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA-β at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Homeostatic Model Assessment of insulin resistance (HOMA-IR) at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HOMA-IR at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in endpoints at 2 hours after the start of the meal for 2-hour PMG and 2-hour incremental PMG at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in endpoints at 2 hours after the start of the meal for 2-hour PMG and 2-hour incremental PMG at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in AUC endpoints (Total AUC and Excursion AUC) for glucose, insulin, C-peptide, proinsulin, proinsulin AUC/Insulin AUC, Insulin AUC/ Glucose AUC at Week 20</measure>
    <time_frame>Baseline and Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in AUC endpoints (Total AUC and Excursion AUC) for glucose, insulin, C-peptide, proinsulin, proinsulin AUC/Insulin AUC, Insulin AUC/ Glucose AUC at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring glycemic rescue therapy at Week 20</measure>
    <time_frame>Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring glycemic rescue therapy at Week 54</measure>
    <time_frame>Week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A (20 weeks): Sitagliptin 100 mg oral tablet once daily prior to the morning meal and placebo to metformin oral tablet (500 mg), 2 tablets twice daily prior to morning and evening meals. Phase B (34 weeks): Participants who have not initiated glycemic rescue therapy will continue to receive Phase A treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A (20 weeks): Placebo to sitagliptin oral tablet once a day and placebo to metformin oral tablets (500 mg), 2 tablets twice daily prior to morning and evening meals. Phase B (34 weeks): Participants who have not initiated glycemic rescue therapy will receive 1 tablet of placebo to sitagliptin daily and 2 tablets of metformin (starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg tablet administered orally once daily</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to sitagliptin</intervention_name>
    <description>Matching placebo to sitagliptin 100 mg tablet administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to metformin</intervention_name>
    <description>Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycemic Rescue 1</intervention_name>
    <description>Participants in the sitagliptin arm who require glycemic rescue will receive metformin in both Phase A and Phase B. Participants in the placebo arm who require glycemic rescue will receive metformin in Phase A. Participants on background insulin will NOT have their insulin doses up-titrated, but will be rescued with metformin.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycemic Rescue 2</intervention_name>
    <description>Participants in the placebo arm who have switched to metformin in Phase B and require glycemic rescue will receive sitagliptin. Participants on background insulin will NOT have their insulin doses up-titrated, but will be rescued with sitagliptin.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glycemic Rescue 3</intervention_name>
    <description>Participants who require glycemic rescue after Glycemic Rescue 1 or 2, will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus (T2DM)

          -  Has not received treatment with an antihyperglycemic agent (AHA) for ≥12 weeks prior
             to the Screening Visit/Visit 1, or is on a stable dose of insulin (without any other
             AHA) for at least 12 weeks prior to the Screening Visit/Visit 1. At screening,
             participants on insulin doses that are not stable can have their insulin doses
             adjusted and be eligible to participate after their dose remains stable for ≥12 weeks,
             if they meet all other eligibility criteria. In India, only participants on stable
             doses of insulin will be eligible.

          -  An A1C of ≥6.5% and ≤10.0% (For participants on insulin: an A1C ≥7.0% and ≤10.0%).

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus, autoimmune diabetes mellitus or has a positive
             antibody screen for anti-GAD (Glutamic Acid Decarboxylase) or (Islet cell autoantigen)
             ICA-512.

          -  Known monogenic diabetes, secondary diabetes, or a genetic syndrome or disorder known
             to affect glucose tolerance other than diabetes.

          -  Symptomatic hyperglycemia and/or moderate to large ketonuria and/or positive test for
             ketonemia requiring immediate initiation of antihyperglycemic therapy.

          -  Previously taken a DPP-4 (Dipeptidyl peptidase-4) inhibitor (such as sitagliptin,
             vildagliptin, alogliptin, or saxagliptin) or (Glucagon-like peptide-1) GLP-1 receptor
             agonist (such as exenatide or liraglutide).

          -  Hypersensitivity or contraindication (according to the product circular in the country
             of the investigational site) to metformin.

          -  Chronic treatment with a medication known to cause weight gain within 30 days of study
             start or weight loss or increased blood glucose within 8 weeks of study start or
             treated with an anti-psychotic within the past 12 weeks.

          -  On a weight loss program and not in the maintenance phase or have undergone bariatric
             surgery within 12 months prior to study start.

          -  On or likely to require treatment with ≥14 consecutive days or repeated courses of
             pharmacologic doses of corticosteroids.

          -  Undergone a surgical procedure within the prior 4 weeks or has major surgery planned
             during the study.

          -  History of congenital heart disease or cardiovascular disease other than hypertension.

          -  Medical history of active liver disease (other than non-alcoholic hepatic steatosis),
             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic
             gallbladder disease.

          -  Active nephropathy (i.e., nephrotic syndrome or glomerulonephritis).

          -  Chronic myopathy, mitochondrial disorder, or a progressive neurological or
             neuromuscular disorder (e.g., polymyositis, or multiple sclerosis).

          -  Human immunodeficiency virus (HIV) as assessed by medical history.

          -  Clinically significant hematological disorder (such as aplastic anemia,
             thrombocytopenia, myeloproliferative or myelodysplastic syndrome).

          -  Under treatment for hyperthyroidism.

          -  Exhibits abnormal growth patterns or is being treated with growth hormone.

          -  History of malignancy or clinically important hematologic disorder.

          -  History of idiopathic acute pancreatitis or chronic pancreatitis.

          -  Known history of recreational or illicit drug use, or of alcohol abuse or dependence
             (within the past year).

          -  Donated blood products or has had phlebotomy of &gt;10% of estimated total blood volume
             within 8 weeks of signing informed consent, or intends to donate blood products or
             receive blood products within the projected duration of the study.

          -  Pregnant, has a positive urine pregnancy test at Screening Visit/Visit 1, is expecting
             to conceive within the projected duration of the study, or is breast-feeding.

          -  Exclusionary laboratory values.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigative Site 0312)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0302)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0018)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0020)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0023)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0337)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0323)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0326)</name>
      <address>
        <city>Thomaston</city>
        <state>Georgia</state>
        <zip>30286</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0333)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0328)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0306)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0017)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0015)</name>
      <address>
        <city>Lytle</city>
        <state>Texas</state>
        <zip>78052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0342)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (Argentina) Inc.</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Wilkinson</last_name>
      <phone>54 11 4796 8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Brasil</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MSD Online</last_name>
      <phone>0800 012 22 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Bulgaria EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Gefen</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre Centre d'information medicale Merck Canada Inc.</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corp.</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Elena Azara Hernandez</last_name>
      <phone>56 2 6558958</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MDS Colombia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Carvajal</last_name>
      <phone>57 1219109011090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya Cedraro</last_name>
      <phone>507-282-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Arbelaez</last_name>
      <phone>(787) 474-8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Gefen</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vianex, S.A. / MSD</name>
      <address>
        <city>Alimos</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lazaros Poughias</last_name>
      <phone>30 2109897322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya Cedraro</last_name>
      <phone>507-282-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Tegucigalpa</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya Cedraro</last_name>
      <phone>507-282-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gally Teper</last_name>
      <phone>972-9-9533310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Nardini</last_name>
      <phone>39 06 361911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UAB &quot;Merck Sharp &amp; Dohme&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Petaling Jaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boon Hock Yeoh</last_name>
      <phone>60 377181723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Port Louis</city>
        <country>Mauritius</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cem Ozesen</last_name>
      <phone>90 212 3361260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Marques</last_name>
      <phone>52 55254819608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Gots</last_name>
      <phone>38 044 393-7480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corporation</name>
      <address>
        <city>Makati</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Recto</last_name>
      <phone>632 784 9500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Johansson</last_name>
      <phone>48 22ý478 43 24</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Romania SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olaru</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Serebriakova</last_name>
      <phone>74959167100, EXT.366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (IA) Corp - SA Branch</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samer El-Ali</last_name>
      <phone>04 4269100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Gefen</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanyi Mzolo</last_name>
      <phone>27 11 655 3140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Thailand) Ltd.</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanu Komolsai</last_name>
      <phone>66 2262 5746</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samer El-Ali</last_name>
      <phone>04 4269100</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Dominican Republic</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Honduras</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mauritius</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United Arab Emirates</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>Panama</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

